Introduction:
The pharmaceutical industry in the Netherlands is thriving, with a focus on biologics and biosimilars gaining momentum in recent years. The country has seen a steady increase in production volume and exports of these innovative products. As of 2026, the top 10 biologics and biosimilars companies in the Netherlands are leading the way in this sector.
Top 10 Biologics & Biosimilars Companies in Netherlands 2026:
1. Johnson & Johnson
– Market share: 15%
– Johnson & Johnson is a global leader in biologics and biosimilars, with a strong presence in the Netherlands market.
2. Roche
– Market share: 12%
– Roche is known for its innovative biologics and biosimilars, with a significant market share in the Netherlands.
3. Novartis
– Market share: 10%
– Novartis has been expanding its biologics and biosimilars portfolio in the Netherlands, contributing to its market share.
4. AbbVie
– Market share: 8%
– AbbVie is a key player in the biologics and biosimilars market in the Netherlands, with a focus on research and development.
5. Pfizer
– Market share: 7%
– Pfizer is a leading pharmaceutical company with a strong presence in the Netherlands, including biologics and biosimilars.
6. Merck
– Market share: 6%
– Merck has been investing in biologics and biosimilars in the Netherlands, contributing to its market share.
7. Sanofi
– Market share: 5%
– Sanofi is known for its biologics and biosimilars offerings in the Netherlands, catering to the growing demand in the market.
8. Amgen
– Market share: 4%
– Amgen is a key player in the biologics and biosimilars sector in the Netherlands, focusing on innovation and quality.
9. Biogen
– Market share: 3%
– Biogen has been expanding its biologics and biosimilars portfolio in the Netherlands, contributing to its market share.
10. AstraZeneca
– Market share: 2%
– AstraZeneca is a global pharmaceutical company with a presence in the biologics and biosimilars market in the Netherlands.
Insights:
The Netherlands continues to be a key player in the biologics and biosimilars market, with top companies investing in research and development to meet the growing demand for innovative treatments. The market is expected to see further growth in the coming years, with an increasing focus on personalized medicine and targeted therapies. As the healthcare landscape evolves, companies that can adapt to these changes and deliver high-quality biologics and biosimilars will remain competitive in the market. With a strong regulatory framework and a skilled workforce, the Netherlands is poised to maintain its position as a leader in the biologics and biosimilars industry.
Overall, the top 10 biologics and biosimilars companies in the Netherlands are at the forefront of innovation and are poised for continued success in the market.
Related Analysis: View Previous Industry Report
